One hundred twenty-one extended-spectrum ␤-lactamse-producing enterobacterial clinical isolates were screened for the qepA gene. A single CTX-M-15-positive Escherichia coli isolate (0.8%) that produced the putative pump QepA2 was identified. This qepA2 gene was located onto a 90-kb mobilizable plasmid that conferred reduced susceptibility to hydrophilic fluoroquinolones.
Although resistance to quinolones in Enterobacteriaceae is related mainly to chromosome-encoded mutations (16) , emergence of plasmid-mediated quinolone resistance has been reported with three known mechanisms to date: the Qnr determinants (12, 15) , aminoglycoside acetyltransferase AAC(6Ј)-Ib-cr (14) , and QepA (13, 19) . Whereas QnrA (10), QnrB (8) , and QnrS (7) proteins protect target enzymes (DNA gyrase and type IV topoisomerases) from quinolone inhibition (12, 15) , the AAC(6Ј)-Ib-cr determinant acetylates norfloxacin and ciprofloxacin (14) .
The QepA determinant has been identified in two Escherichia coli clinical isolates from Japan and Belgium (13, 19) . The qepA gene encodes a 14-transmembrane-segment efflux pump belonging to the major facilitator superfamily (13, 19) . QepA confers decreased susceptibility to hydrophilic fluoroquinolones (e.g., norfloxacin, ciprofloxacin, and enrofloxacin) with a 32-to 64-fold increase of MICs (13, 19) . To date, a single epidemiological survey has evaluated the prevalence of the QepA determinant among a collection of E. coli clinical isolates collected from 2002 to 2006 (cutoff of MICs of norfloxacin, Ն0.025 g/ml), reporting its low prevalence (0.3%) in Japan (18) .
In order to determine whether that determinant may have disseminated further worldwide, we have conducted an epidemiological survey to evaluate the prevalence of the qepA gene among extended-spectrum ␤-lactamase (ESBL)-producing enterobacterial isolates collected from a French university hospital, since ESBLs are often identified among quinolone-resistant isolates (12, 15) .
One hundred twenty-one nonduplicate, ESBL-producing enterobacterial clinical isolates, collected at the Bicêtre Hospital, France, between January and October of 2007 have been studied. Screening was carried out by PCR using standard conditions and specific primers designed in this work: qepA-F (5Ј-CGTGTTGCTGGAGTTCTTC-3Ј) and qepA-R (5Ј-CTG CAGGTACTGCGTCATG-3Ј), giving a 403-bp product. The qepA gene was detected in a single E. coli isolate, indicating its low prevalence (0.8%) in that collection. Similarly, a low prevalence has also been reported (0.3%) in E. coli (18) from Japan. This work is the first epidemiological survey of the QepA determinant performed with European isolates. To date, only four qepA-positive clinical isolates have been reported from Japan and Belgium, all being E. coli isolates (13, 18, 19) .
The qepA gene was identified in E. coli isolate BicA recovered in January 2007 from urine and blood samples of a 79-year-old female patient suffering from pyelonephritis. Antibiotic susceptibility testing by disk diffusion revealed that E. coli BicA was resistant to all ␤-lactams except carbapenems and cephamycins and exhibited an ESBL phenotype. PCR and sequencing (6) revealed that E. coli BicA harbored the bla TEM-1 and bla CTX-M-15 genes and was also resistant to chloramphenicol, tetracycline, sulfamethoxazole, trimethoprim, nalidixic acid, and fluoroquinolones but remained fully susceptible to aminoglycosides (Table 1) , according to the CLSI standard (5) . Sequence analysis of the chromosome-encoded quinolone resistance-determining regions (2) revealed that E. coli BicA had a gyrA gene with two mutations, leading to Ser83Leu and Asp87Asn substitutions, and one mutation in parC, leading to a Ser80Ile substitution, compared to the wild-type enzymes of E. coli. No mutation was found in gyrB and parE genes, and no qnr-like or aac(6Ј)-Ib-cr genes were detected by PCR (4, 11) in E. coli BicA.
The QepA determinant was transferred as previously described (3) from E. coli BicA to the E. coli TOP10 recipient strain by electrotransformation after selection on Trypticase soy agar plates containing ciprofloxacin (0.01 g/ml). Plasmid analysis performed by using the Kieser technique (9) identified a single ca. 90-kb plasmid (pQep) from the E. coli transformant. PCR-based replicon typing (1) indicated that pQep was a member of the IncFI incompatibility group. Once transferred in E. coli TOP10, pQep conferred increased MICs for hydrophilic fluoroquinolones (such as norfloxacin and ciprofloxacin) as previously described (13, 19) and also increased resistance to amoxicillin, ticarcillin, piperacillin, chloramphenicol, tetracycline, sulfamethoxazole, and trimethoprim (Table 1 ). In addition, plasmid pQep was confirmed by PCR (6) to harbor the bla TEM-1 gene but not the bla CTX-M-15 gene. A second plasmid pCTX-M of ca. 90 kb and identified as an IncI1-type plasmid carried the bla TEM-1 and bla CTX-M-15 genes that were transferred by conjugation into E. coli J53 after selection with amoxicillin. Transconjugants containing only pCTX-M (TC-1) exhibited an ESBL phenotype without any coresistance (Table 1) . Noteworthy, pQep was cotransferred with pCTX-M but was not identified alone after selection with chloramphenicol, suggesting that pQep might be on October 14, 2017 by guest http://aac.asm.org/ mobilizable and not conjugative, as opposed to pIP1206, which is also classified as a broad-host-range IncFI-type plasmid (13) . Cloning of HindIII-restricted DNA from whole-cell DNA (3) of E. coli BicA gave recombinant plasmid pRBicAH, containing a 7,020-bp insert including the qepA gene. Sequence analysis revealed that the qepA gene was located inside a genetic structure in large part identical to that of previously described plasmids pHPA (19) and pIP1206 (13) , identified from qepA-positive E. coli strains from Japan and Belgium, respectively (Fig. 1) . However, detailed analysis of pRBicAH showed that the qepA gene possessed two nucleotide substitutions, leading to Ala99Gly and Val134Ile changes in the deduced 511-amino-acid protein (13, 19) . This variant (named QepA2) conferred a phenotype similar to that of the QepA determinant (renamed QepA1) (data not shown). Of note is the fact that the qepA2 gene was not associated with the rmtB gene encoding an aminoglycoside ribosomal methylase, in contrast to what has been reported for plasmids pHPA and pIP1206 (13, 19) . Interestingly, the qepA2 gene was identified between two copies of an ISCR-like element and was not associated with IS26 elements, as opposed to what was described in pHPA (Fig. 1) . The transposase gene of that ISCR element encoded a protein 100% identical to the putative transposase identified on plasmids pHPA and pIP1206 (13, 19) . That transposase showed a single amino acid substitution, Leu331Arg or Leu477Pro, compared to transposases of the ISCR3-like elements ISCR3A (GenBank accession no. AAK02053, AF261825, BAE54320, and ABZ01838) and ISCR3B (GenBank accession no. ACA62823), respectively. This novel IS element was termed ISCR3C. Upstream of the qepA2 gene, a truncated dfr2 gene known to encode resistance to trimethoprim was identified and was located upstream of a truncated integrase gene (⌬intI1) of a class 1 integron (Fig. 1 ). This truncated integrase gene was identified close to a truncated chaperonin gene (⌬groEL), thus encoding a fusion protein IntI1/GroEL previously described in association with ISCR-like elements (17) . In a study of E. coli C316 from Japan, the region comprising the qepA and rmtB genes was found to be flanked by two copies of IS26, and the authors suggested that those genes were likely part of a composite transposon (Fig. 1) (19) . In pQep, the genetic environment of the qepA2 gene was nearly identical to that of pHPA, but no IS26 element was found. The ISCR3-type element might be at the origin of the mobilization of the qepA2 gene, and a possible hypothesis reconstituting the overall process of acquisition of that gene (involving transposition/recombination mechanisms) is proposed in Fig. 2 , according to the model described by Toleman et al. (17) .
By using a 5Ј rapid amplification of cDNA ends PCR system (Invitrogen, Cergy-Pontoise, France), the site of initiation of transcription of the qepA2 gene was mapped in E. coli BicA and identified 24 bp upstream of the start codon of that gene. Upstream of this transcriptional start site, a putative Ϫ35 promoter sequence (ATGTCG) was found, separated by 17 bp from a putative Ϫ10 promoter sequence (TGTCGT). A putative ribosome binding site (GGAAG) was also identified 9 bp upstream of the qepA2 start codon. This is the first epidemiological survey evaluating the prevalence of the plasmid-mediated quinolone resistance determinant QepA in a European hospital; the prevalence was found to be low among ESBL-producing enterobacterial isolates. Identification of QepA with the widespread ESBL CTX-M-15 on a broad-host-range plasmid and in association with a peculiar ISCR-mediated genetic structure may indicate its further spread.
Nucleotide sequence accession number. The nucleotide sequence of the qepA2-positive strain E. coli BicA has been submitted to the GenBank nucleotide sequence database (accession no. EU847537).
